Page 94 - 2020_09-Haematologica-web

A.L. Sørensen et al.
26. Barbui T, Carobbio A, Rumi E, et al. In con-
temporary patients with polycythemia vera, rates of thrombosis and risk factors delin- eate a new clinical epidemiology. Blood. 2014;124(19):3021-3023.
27. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated inter- feron alpha-2a. Blood. 2013;122(6):893-901.
28. Utke Rank C, Weis Bjerrum O, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorpho- logical response patterns in 10 patients with essential thrombocythemia and poly- cythemia vera. Leuk Lymphoma. 2016;57 (2):348-354.
29. Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30.
30. Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96(7):1113-1120.
31. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symp- tom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring sys- tem among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103.
32. Larsen TS, Pallisgaard N, Moller MB, et al. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia. 2008;22(1):194-195.
33. Kjaer L, Cordua S, Holmstrom MO, et al. Differential dynamics of CALR mutant allele burden in myeloproliferative neo- plasms during interferon alfa treatment.
PLoS One. 2016;11(10): e0165336.
34. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group- Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Blood. 2013;122(8):1395-1398.
35. Barosi G, Mesa R, Finazzi G, et al. Revised
response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778-4781.
36. Kiladjian J-J, Soret-Dulphy J, Resche-Rigon M, et al. Ruxopeg, a multi-center Bayesian phase 1/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myelo- proliferative neoplasm (MPN)-associated myelofibrosis. Blood. 2018;132 (Suppl 1):581-581.
37. Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis. Cancer. 2017;123(14):2680-2687.
38. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24): 6669-6672.
39. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018;11(1):42.
40. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treat- ment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
41. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombo- sis. Blood. 2013;122(13):2176-2184.
42. Gisslinger H, Zagrijtschuk O, Buxhofer- Ausch V, et al. Ropeginterferon alfa-2b, a
novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15): 1762-1769.
43. Gisslinger H, Klade C, Georgiev P, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of poly- cythemia vera patients with ropeginterferon alfa-2b Vs. HU/BAT. Blood. 2018;132(Suppl 1):579-579.
44. Mesa RA, Kosiorek HE, Mascarenhas J, et al. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha- 2a vs. hydroxyurea in high risk poly- cythemia vera and essential thrombo- cythemia: results of myeloproliferative dis- orders research consortium (MPD-RC) 112 global phase III trial. Blood. 2018;132(Suppl 1):3032-3032.
45. Deininger M, Radich J, Burn TC, et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551- 1554.
46. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neo- plasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011;2(1):21-32.
47. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refrac- tory or intolerant to hydroxyurea. Cancer. 2014;120(4):513-520.
48. Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treat- ment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41(1):5-19.
49. Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98(5):1071-1082.
2272
haematologica | 2020; 105(9)